Methods Our acute hospital's spend on inhaled therapy is high, and was rising year on year. It is recognised that 'stockpiling' of inhaled therapy occurs, and that patients often don't bring in their inhalers when admitted acutely. In October 2016 we drew up guidelines for our hospital pharmacists aiming to support them in safely deferring dispensing inhalers, allowing time for patients to arrange for inhalers to be brought in from home. We developed a flow chart, with posters displayed on the medical wards as reminders. In addition we encouraged pharmacists not to dispense a new type of inhaler unless the patient had been assessed as able to use it by the Respiratory Nurse Specialist. From April 2016 we also started actively changing patients from high cost to lower cost devices, matching the local CCG prescribing incentive scheme for 2016-2017.
Results Following the 'Defer Dispensing' programme there was a 28% reduction in spend on inhaled therapy and a 6.5% reduction in the number of items dispensed, (See Table) . Using 2016-2017 figures the average cost of inhalers dispensed was £14.21, giving a saving of £10 757 related to reduced number of items dispensed. In the first 3 months of this year (2017-2018) there has been an additional 23% cost reduction compared to previous year's equivalent time period and a 5.2% reduction in number of items dispensed.
Conclusion There is scope to impact on respiratory pharmacy spend in acute trusts. This was achieved both by swapping to lower cost preparations, with ongoing benefit to the local health economy, plus a reduction in the number of items dispensed. We believe that there is potential for further savings by making dispensing of inhaled therapy a more robust process.
Abstract M3 Table 1 Financial -2017-210983.426 Introduction and Objectives An average of 40% of Chronic Obstructive Pulmonary Disease (COPD) patients suffer from clinical depression and anxiety disorders, at least twice as much as reported by the general population. In COPD patients, comorbid mental health problems significantly predict more frequent symptom exacerbation, inpatient admissions, poorer functional status and quality of life due to reduced self-care. Typically up to 50% of treated COPD patients reported improvements of depression and anxiety symptoms after psychological therapy. However, conventional mental health services (e.g., Improving Access to Psychological Therapies services) have experienced challenges in engaging, assessing, and treating this patient group. The current study explores the clinical outcomes of a psychology service integrated into the existing COPD management frameworks and pulmonary rehabilitation programs in the London Borough of City and Hackney; in particular its impact on patients' access to psychological therapy, changes in mental health symptoms, quality of life and patient experiences of COPD. 
